Abstract
While, currently, awide spectrum of drugs that can be eective in both primary and secondary prevention of diabetic kidney disease are available for clinical use, in many cases, they may not be eective enough or even fail. Antidiabetic agents can work through amechanism independently of glycemia control or direct renoprotective eects.
The question is whether the choice of antidiabetics depends on diabetes duration, presence of macrovascular complications and the presence and severity of kidney disease. We do know that preventing the onset or slowing the progression of diabetic kidney disease helps reduce the risk of cardiovascular complications in diabetic patients.
Therefore, it is advisable to choose drugs that do not impair renal function. When choosing antidiabetics, it should also be borne in mind that diabetic kidney function is labile compared to people without diabetes.
Acute exacerbations such as illness or various therapeutic interventions should likewise be considered. It is preferable to choose drugs whose dosing is independent of renal function.
